For the Quarter Ending December 2022
In the 4th quarter of 2022, the North American market for Ritonavir experienced a small decline, with prices falling from $714850/mt to $706500/mt from October to December. Due to China's Golden Week vacation in early October, Ritonavir imports got delayed. Due to adequate product inventories and favorable offtakes in the end-user industries, domestic suppliers were able to meet the demand for most of the quarter. A sudden increase in Covid cases in China at the conclusion of the quarter caused a pattern shift in the market for Ritonavir. However, as the economy improved and the backlog at the ports significantly decreased, the broken supply chain started to heal.
The fourth quarter of 2022 saw no notable changes in the price of Ritonavir in the Asia Pacific region. From October to December, prices for FOB Shanghai in China decreased somewhat, from $650000/MT to $646580/MT. Due to production facilities being shut down for the Golden Week during the first week of October, orders for Ritonavir for China's pharmaceutical API market gradually fell. Chinese suppliers and producers were able to meet the demand for the full quarter thanks to an abundance of supplies. The administration altered its zero-covid laws in response to criticism and significant instability in the nation in December, leaving the nation vulnerable once more.
The market for Ritonavir in the European region showed an upward trajectory as prices in Germany increased from $691770/mt to $707200/mt between October and November. Despite the unexpected rise in COVID cases, end-user demand appeared to be healthy and overseas demand was higher in the first half of the quarter than it was in December. Germany's demand remained high despite growing costs for energy and raw materials in the end-user industries. Irrespective of the optimism illustrated by improved sentiment indicators, China's covid impact, the Russia-Ukrain Situation, drop in orders, and build-up inventories combinedly demonstrated an ill outlook.
For the Quarter Ending September 2022
The market trend for Ritonavir API experienced an increasing trajectory during the third quarter of 2022. Ritonavir, a significant pharmaceutical API import, got severely affected by the exporting countries, including China and India, because of zero covid policies imposed in the Chinese market. In the H1 of the third quarter, the price value of Ritonavir API rose considerably, backed by healthy demand from end-user pharmaceutical sectors. Furthermore, towards the termination and start of h3, the prices went down at a steady rate owing to the weaker trader compared to the previous two months in q3. Overall, in the third quarter, the value displayed for Ritonavir was settled at USD 708500/MT CFR Los Angeles in the United States.
The Ritonavir API market showcased an increasing pricing trend in the APAC region throughout the third quarter of 2022. In the Chinese market, the prices inclined steadily in the first half of q3 owing to healthy offtakes in the domestic market. Furthermore, the demand in the h2 also went on the higher side with lower inventories. Some manufacturing activities decreased owing to worsened weather conditions, supporting the suppliers to increase their rates to gain profits. On the other hand, in India also, similar market sentiments were observed throughout the q3. Over the last weeks in China, The market dynamics of Ritonavir in the third quarter have been poorly influenced by extreme weather and economic issues, which resulted in weaker offtakes. The price for Ritonavir API in China was USD 654000/MT FOB Shanghai.
In the European region, Ritonavir API prices witnessed a decreed trend in the third quarter of 2022. Weak demand with enough stocks was experienced in the German market during the first half of q3, which kept the price value of Ritonavir on the lower side. Further, towards the start of h2, the demand increased stably, resulting in higher prices. Moreover, the Russian-Ukraine war and disrupted trading activities supported Ritonavir's market sentiments during the end of the third quarter in Germany. Overall, towards the end of q3, the prices demonstrated for Ritonavir API were settled at USD 717970/MT CFR Hamburg in September.
The North American region witnessed a varied price difference in Ritonavir during the second Quarter of 2022. Ritonavir's price increased during the First Half of the Second Quarter due to its raised Upstream Raw material Valine prices. Furthermore, the supply disruption and interrupted export activities from various regions resulted in the price increment of Ritonavir in the overall regional and domestic Market. Towards the second Half of the second quarter, the demand for Ritonavir reduced stiffly, affecting the Market negatively. Further, towards the end of the Second Quarter, the price augmented the demand from various end-user manufacturing enterprises. Towards the end of Q2 the price recorded for Ritonavir witnessed were settled at USD 700000/MT CFR Los Angeles in Untied States.
The Ritonavir market in the Asia Pacific region witnessed a prominent price increment during the second Quarter of 2022. In the first half of Q2, the prices of Ritonavir rose significantly, with an ongoing Lockdown in some regions of APAC. Also, the labour shortage amid social distancing norms and the closure of commercial activities in China augmented Ritonavir API prices. Furthermore, the supply was halted in India, one of the major exporters of Ritonavir drugs in the overall region, resulting in a price hike of Ritonavir API, due to which India started Manufacture Ritonavir API in their region. The prices increased due to heightened Upstream Raw material L-valine prices in the Market. During the second half of Q2, the Ritonavir market witnessed reduced demand, leading to stockpiling inventories with the market traders. Towards the end of the second quarter, the prices of Ritonavir settled at INR 39000000/MT USP Ex Ahmedabad India.
During the Second Quarter of 2022, the European Market witnessed Unstable price trends of Ritonavir API. In the first half of Q1, Ritonavir API prices declined in the European region as the downstream demand for Ritonavir-based drugs reduces from various end-user sector. Furthermore, the Russian- Ukraine geopolitical tension and delayed shipments supports the market sentiments of Ritonavir. In addition, another factor that resulted in the price decrement of Ritonavir API in the Market was weak customer requirements. Altogether, towards the end of Q2 the prices for Ritonavir settled at USD734270/MT CFR Hamburg IN Germany.